|
NEWLY
acquired Smart subsidiary Connectivity Unlimited
Resource Enterprise (CURE) yesterday launched ümobile,
the first ad-funded mobile-phone service in Asia.
Commercial launch is set on June 1, officials said.
CURE
chief marketing officer Ardie Balderrama said the
cellular firm, the newest player in the telco market,
will compete with other mobile-phone firms by giving out
free load credits to subscribers who receive
advertisements via their 2G- (second-generation) or
3G-enabled handsets.
“For our
subscribers, it will be like earning money by watching
commercials on television or viewing print ads in
newspapers and magazines, except they will do it through
their ümobile phones,” said Balderrama. CURE is a
licensed 3G operator in the country.
CURE
will partner with corporations that wish to advertise or
create mobile-based campaigns for a particular brand. A
portion of the revenues generated from a brand’s
mobile-marketing campaigns will be given back to the
subscribers who can purchase or make transactions for
ümobile services or avail themselves of a brand’s
product offer, such as freebies, discounts and other
rewards.
CURE
sales head Noli Romualdez said the company is set to
partner with five to 10 companies prior to the
commercial launch of ümobile. “We are in advance talks
with them. They are all very interested about it. They
are in the food business, beauty products, and goods and
services businesses, and even financial institutions,”
he said.
ümobile
will focus on a niche market composed of men and women
aged 15 to 35. Forty-five percent of the population
belongs to this age segment, where brand preference and
loyalty is built.
Subscription will be by-invitation and only around
10,000 subscribers are expected every month. Subscribers
accepted into the service from June to August will get
P100 worth of prepaid load every month for six months.
On top of that, every ad message they view on their
ümobile phone earns them rewards in the form of free
load, text messages, data minutes, etc.
Additional freebies will be given based on their
participation in mobile- marketing campaigns by
advertisers in the ümobile network.
“Through ümobile, we offer advertisers the opportunity
to tap into their emerging marketing medium where they
can directly target the consumers they want to reach.
We’ll know if our subscribers go to the gym, what movies
they watch, what kind of music they listen to, among
other things, and this will allow to cater to the prime
prospects of our advertisers,” said Balderrama.
By the
end of this year, CURE expects it would register up to
100,000 subscribers.
While
other mobile-phone operators have their versions of
unlimited voice and text messaging services, CURE’s
business model is anchored on bringing together brands
and consumers closer via mobile-phone services. “This is
how CURE will compete in the mobile telco arena,” added
Balderrama.
ümobile
will ride on the network of Smart Communications Inc.,
the cellular unit of Philippine Long Distance Telephone
Co. (PLDT). CURE has already forged interconnection
agreements with the PLDT group, which means that CURE
subscribers can call and send text messages to Smart and
Piltel cellular subscribers, PLDT landline users and
vice versa.
CURE
will pay Smart for the use of the latter’s network.
Balderrama did not reveal details of the commercial
arrangement between the two networks. “Our coverage
within Metro Manila is only 30 cellular sites. Outside
of Metro Manila, we will tap on Smart’s network,” he
added.
CURE is
confident that it will ink similar interconnection deals
with Globe Telecom, Sun Cellular and Bayan
Telecommunications Inc. prior to the commercial launch.
Smart
recently purchased the entire issued and outstanding
capital stocks of PH Communications Holdings Corp. and
Francom Holdings, Inc. (FHI) in CURE for the total
amount of P419.54 million. PH Communications used to own
96.57 percent of CURE while FHI had 3.43 percent stake
in the 3G firm. Both were controlled by an investor
group led by businessman Roberto Ongpin.
Smart
said it intends to directly invest up to P210 million in
CURE, in the form of subscriptions for new shares. The
fresh funds will be used for working capital. |